Shares of Altimmune (NASDAQ:ALT) traded sharply higher on Friday after the obesity drug developer generated buyout rumors on ...

Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.

Consider issues related to the lack of workforce diversity, lessons learned from related fields, and approaches for engaging and preparing a more diverse person-centered drug R&D workforce, ...

Drug development has long been an issue for the ... hopes to involve five million adult volunteers. The future of R&D The Our Future Health project was funded from various bodies, but the pharma ...

patients can wait more than ten years from initial drug discovery to its availability as a treatment. With autoimmune diseases and cancer rates increasing, the pharmaceutical industry’s R&D ...

Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing. Fosun Pharma’s ...

There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen. After a year ...

Among the emerging players, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing. Aiming to be a leading healthcare group with a ...

Keytruda, a cancer medicine, ranks among the most lucrative drugs ever sold. Since its launch in 2014 it has raked in more than $130bn in sales for Merck, its American maker, including $29.5bn ...